Japanese Encephalitis Vaccine (JEV)
Pre-Solicitation Posted
A newer pre-solicitation was posted. See the latest pre-solicitation from .
- Solicitation number
- SPE2DP-23-R-0001
- Agency
- Medical Supply Chain Troop Support, Department of Defense
- Responses due
- Not on record
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support is seeking sources capable of providing the Japanese Encephalitis Vaccine. The agency contemplates awarding a one-year base contract with a one-year option for an indefinite quantity of 200,000 to 300,000 doses annually. The vaccine must be purified, inactivated, cell-culture derived, preservative free, licensed by the FDA, and approved for intramuscular administration to persons 2 months and older. Firms must have FDA approval to sell the vaccine prior to award. Responses to this request for information are due by email no later than April 28, 2023 and will be kept confidential and protected as critical infrastructure information.
No set-aside designation will be used. The estimated annual quantity to be ordered is 200,000 minimum doses and 300,000 maximum doses for the base year, and 160,000 to 260,000 doses for the option year. Current manufacturers must provide place of manufacture, annual capacity, FDA registration, product description and special features, current unit price, and estimated inventory levels and storage requirements. Firms developing new vaccines should describe the development stage and any independent or FDA testing completed. The NAICS code is 325412 with PSC code 6515, and the incumbent contractor is unknown.
Notice text
2 versions
Update #2 · Latest ·
The Defense Logistics Agency Troop Support is seeking sources capable of providing the Japanese Encephalitis Vaccine (JEV). DLA Troop Support is contemplating awarding a one-year base and a one year option, indefinite quantity contract for the JEV. The estimated annual quantity to be ordered is 200,000 doses minimum and 300,000 doses maximum for the base year and 160,000 doses minimum and 260,000 doses maximum for option year 1. However, the quantity may increase or decrease as the Services requirements change.
The vaccine shall be purified, inactivated, Vero Cell culture derived, contain no stabilizers, Thimerosal/Preservative free, Latex free, licensed by the Food and Drug Administration (FDA), suitable for intramuscular administration and intended for active immunization against Japanese Encephalitis disease. The vaccine shall be a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle. The vaccine must be approved by the FDA for administration to persons 2 months of age and up.
Must have FDA approval to sell the JEV before award of the contract.
If your firm currently manufactures or distributes the JEV, please provide information with respect to the following:
a) Place of manufacture
b) Estimated annual capacity
c) FDA registration
d) Product name and description including description of any special features
e) Current unit sale price
f) Estimated inventory level and storage requirements
*** NEW PRODUCTS UNDER DEVELOPMENT***
For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the JEV or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.
Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the JEV. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement.
Your response to this RFI may be submitted electronically in pdf format and emailed to danielle.delaney@dla.mil by May 21, 2023 3pm EST.
Update #1 ·
The Defense Logistics Agency Troop Support is seeking sources capable of providing the Japanese Encephalitis Vaccine (JEV). DLA Troop Support is contemplating awarding a one-year base and a one year option, indefinite quantity contract for the JEV. The estimated annual quantity to be ordered is 200,000 doses minimum and 300,000 doses maximum for the base year and 160,000 doses minimum and 260,000 doses maximum for option year 1. However, the quantity may increase or decrease as the Services requirements change.
The vaccine shall be purified, inactivated, Vero Cell culture derived, contain no stabilizers, Thimerosal/Preservative free, Latex free, licensed by the Food and Drug Administration (FDA), suitable for intramuscular administration and intended for active immunization against Japanese Encephalitis disease. The vaccine shall be a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle. The vaccine must be approved by the FDA for administration to persons 2 months of age and up.
Must have FDA approval to sell the JEV before award of the contract.
If your firm currently manufactures or distributes the JEV, please provide information with respect to the following:
a) Place of manufacture
b) Estimated annual capacity
c) FDA registration
d) Product name and description including description of any special features
e) Current unit sale price
f) Estimated inventory level and storage requirements
*** NEW PRODUCTS UNDER DEVELOPMENT***
For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the JEV or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.
Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the JEV. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement.
Your response to this RFI may be submitted electronically in pdf format and emailed to danielle.delaney@dla.mil.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Japanese Encephalitis Vaccine (JEV) | Pre-Solicitation | |
| Japanese Encephalitis Vaccine (JEV) | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity